Severe Eczema Linked to Stunted Growth in Children: New Clinical Findings

A new peer-reviewed study from Trinity College Dublin, published in the Journal of the American Academy of Dermatology, reports that children with severe atopic dermatitis are measurably shorter than population norms — and that the targeted biologic dupilumab can partially reverse that growth deficit. For a condition often downplayed as merely a rash, height velocity is the kind of hard endpoint pediatricians have long suspected was being quietly lost, but rarely saw quantified inside a controlled trial design.

What the cohort actually showed

The team analyzed growth and bone biomarkers in 123 children aged 6 to 11 with severe eczema, working from clinical trial data originally gathered in collaboration with Regeneron and Sanofi. At baseline, children with severe atopic dermatitis sat below average height for age. Within the subset already showing growth restriction at enrollment, those randomized to dupilumab gained height at a faster rate than untreated peers over the first 16 weeks — the difference reached statistical significance, which is not always a given in secondary growth analyses of a cohort this size. After week 16, the placebo arm crossed over to active drug and caught up. Serum markers of new bone formation moved in parallel with the clinical height velocity, giving the anthropometric result a biological correlate rather than reading as a statistical artifact.

What the trial doesn't tell us

Several caveats deserve airtime. The 16-week observation window is short for a growth endpoint in school-age children, where puberty, nutrition, and chronic topical or systemic corticosteroid exposure can each confound longitudinal height gain. The investigators themselves note that the mechanism remains unresolved: reduced systemic inflammation, restored sleep architecture, and a drop in cumulative steroid dose are all plausible drivers and cannot be separated in this dataset. The cohort was also drawn from registrational trials rather than a general dermatology clinic — meaning the children studied skew toward the severe end already eligible for biologic therapy, and the findings say little about mild-to-moderate disease where growth impairment is presumably less pronounced.

What it means at the clinic door

For clinicians weighing early dupilumab initiation in a 7-year-old with refractory AD and a flattening growth curve, this is the cleanest signal yet that treating the skin may not be a purely cosmetic decision — it is also a developmental one. It argues that failure-to-thrive workups in severe eczema should explicitly document serial height velocity before reflexively chasing endocrine or gastrointestinal referrals. In my experience running these cohorts, parents rarely raise growth as a concern; they should. The remaining questions for the field are whether the height gains persist past 16 weeks, whether the catch-up translates into final adult height, and whether intervening earlier — before restriction is established — prevents the deficit altogether. That trial has not yet been designed, and without it, payers will continue to have a defensible reason to delay biologic initiation in children who are merely severe, not catastrophically so.